A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate
(vitamin C) to standard radiation and chemotherapy for initial treatment of glioblastoma
multiforme (GBM).
Phase:
Phase 1
Details
Lead Sponsor:
Joseph J. Cullen, MD, FACS University of Iowa
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)